Altria Group (MO) Stock Overview
Through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 6/6 |
MO Community Fair Values
Create NarrativeSee what 383 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Altria Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$69.12 |
| 52 Week High | US$74.56 |
| 52 Week Low | US$54.70 |
| Beta | 0.50 |
| 1 Month Change | -6.59% |
| 3 Month Change | 7.21% |
| 1 Year Change | 16.19% |
| 3 Year Change | 57.95% |
| 5 Year Change | 45.73% |
| Change since IPO | 29,555.94% |
Recent News & Updates
Seeking Alpha • Jun 18
Altria: Gains Might Go Up In Smoke - Strong Sell Rating Confirmed
Summary Altria is rated a strong sell due to accelerating negative momentum in its core cigarette business and eroding market leadership. Marlboro’s U.S. market share has fallen from 44% in 2015 to below 40% in 2026, with volumes collapsing over 10% year-over-year. MO’s reliance on aggressive pricing to offset steep volume declines is unsustainable, as 90% of sales and operating income remain cigarette-driven. With an EV/FCF multiple of 15x and no growth, downside risk is significant if volume declines persist or accelerate. Read the full article on Seeking AlphaAnalysis Article • Jun 17
Altria Group (MO) Stock Could Be 7.2% Overvalued After Share Price Dip And Insider Selling
Altria Group (MO) is back in focus after a 3.3% share price decline, sparked by commentary that the stock trades above estimated intrinsic value and paired with insider share sales over the past three months. See our latest analysis for Altria Group. Putting the recent 3.3% drop in context, Altria Group’s share price return is up 22.47% year to date and 7.77% over 90 days, while the 1 year total shareholder return is 27.06% and 5 year total shareholder return is 118.67%. This suggests...
Narrative Update • Jun 15
MO: Future Returns Will Hinge On FDA Nicotine Product Decisions
Altria Group's updated analyst price target has shifted modestly to $64. This reflects a series of upward revisions as analysts factor in potential next generation product growth following recent FDA guidance.Narrative Update • Jun 01
MO: Future Returns Will Depend On FDA Vape Timing Despite Softer Volume Declines
Altria Group's fair value estimate has moved from $51.95 to $59.00, as analysts point to a modestly lower discount rate, slightly higher assumed revenue growth, a higher future P/E multiple, and a series of rising Street price targets tied to expectations for faster growth in next generation tobacco products following recent FDA guidance. Analyst Commentary Street research on Altria Group has leaned toward higher price targets, but the tone is not uniformly bullish.Recent updates
Seeking Alpha • Jun 18
Altria: Gains Might Go Up In Smoke - Strong Sell Rating Confirmed
Summary Altria is rated a strong sell due to accelerating negative momentum in its core cigarette business and eroding market leadership. Marlboro’s U.S. market share has fallen from 44% in 2015 to below 40% in 2026, with volumes collapsing over 10% year-over-year. MO’s reliance on aggressive pricing to offset steep volume declines is unsustainable, as 90% of sales and operating income remain cigarette-driven. With an EV/FCF multiple of 15x and no growth, downside risk is significant if volume declines persist or accelerate. Read the full article on Seeking AlphaAnalysis Article • Jun 17
Altria Group (MO) Stock Could Be 7.2% Overvalued After Share Price Dip And Insider Selling
Altria Group (MO) is back in focus after a 3.3% share price decline, sparked by commentary that the stock trades above estimated intrinsic value and paired with insider share sales over the past three months. See our latest analysis for Altria Group. Putting the recent 3.3% drop in context, Altria Group’s share price return is up 22.47% year to date and 7.77% over 90 days, while the 1 year total shareholder return is 27.06% and 5 year total shareholder return is 118.67%. This suggests...Narrative Update • Jun 15
MO: Future Returns Will Hinge On FDA Nicotine Product Decisions
Altria Group's updated analyst price target has shifted modestly to $64. This reflects a series of upward revisions as analysts factor in potential next generation product growth following recent FDA guidance.Narrative Update • Jun 01
MO: Future Returns Will Depend On FDA Vape Timing Despite Softer Volume Declines
Altria Group's fair value estimate has moved from $51.95 to $59.00, as analysts point to a modestly lower discount rate, slightly higher assumed revenue growth, a higher future P/E multiple, and a series of rising Street price targets tied to expectations for faster growth in next generation tobacco products following recent FDA guidance. Analyst Commentary Street research on Altria Group has leaned toward higher price targets, but the tone is not uniformly bullish.Narrative Update • May 04
MO: Future Returns Will Depend On Illicit Trade Progress Despite Softer Volume Declines
Altria Group's updated analyst price target edges higher to about $51.95 from $51.79. This reflects analysts' use of a slightly lower discount rate, a modestly less sharp revenue growth decline, and a marginally higher future P/E assumption, even as profit margin expectations ease a bit.Narrative Update • Apr 18
MO: Future Returns Will Depend On Illicit Trade Progress Not Volume Stabilization
Altria's updated fair value estimate edges down from $52.11 to $51.79 per share as analysts refine their price targets around moderating cigarette volume declines, improving trends in next generation products, and ongoing efforts to address illicit trade. Analyst Commentary Recent Street research shows a mix of enthusiasm and caution on Altria Group, with several firms moving their price targets higher while still flagging meaningful execution and growth risks.
Narrative Update • Apr 04
MO: Illicit Trade Controls And Slower Volume Declines Will Shape Future Returns
Analyst price targets for Altria Group have moved higher, with several firms lifting their views by $4 to $8 per share as analysts point to moderating U.S. cigarette volume declines, potential stabilization in Altria's market share, and improvements in addressing illicit trade. Analyst Commentary Recent research updates show a mix of optimism and caution around Altria Group, with several firms adjusting price targets and reassessing how the cigarette and next generation product trends could affect valuation and execution risk.Narrative Update • Mar 20
MO: Illicit Trade Controls And Volume Trends Will Shape Future Earnings Visibility
The updated analyst price target for Altria Group has been raised to $65.50 from $63.92. Analysts cite moderating U.S. cigarette volume declines, efforts to address illicit trade, and expectations for tobacco stocks as supporting factors behind the change.Narrative Update • Mar 06
MO: Future Returns Will Hinge On Illicit Trade Efforts And Volume Pressures
Altria Group's updated fair value estimate has moved from $48.22 to $52.11 as analysts lift price targets into the $63 to $72 range, citing improving tobacco industry fundamentals, efforts to address illicit trade, and expectations for accelerating next generation product growth. Analyst Commentary Recent research commentary on Altria Group shows a mix of optimism and caution, with higher price targets sitting alongside concerns about execution and growth in next generation products.Narrative Update • Feb 20
MO: Illicit Trade Controls And Leadership Changes Will Shape Earnings Visibility
The updated Analyst Price Target for Altria Group edges higher to $63.92 from $63.83. Analysts note that gradual improvements in illicit trade controls and earnings visibility support a slightly richer valuation multiple, despite more conservative revenue growth assumptions.Narrative Update • Jan 26
MO: Future Returns Will Hinge On Persistent Premium Share And Volume Pressures
Narrative Update: Altria Group (MO) Analysts are fine tuning their Altria outlook, with a modestly lower implied future P/E and slightly higher assumed revenue growth and profit margin supporting a price target reset that reflects recent rating changes and views that cigarette volume pressures may be stabilizing alongside mixed brand trends and earnings visibility. Analyst Commentary Recent research on Altria highlights a mix of optimism on earnings visibility and caution around brand mix, category share, and how much investors are willing to pay for the stock.Narrative Update • Jan 12
MO: Future Returns Will Depend On Persistent Premium Brand And Share Pressures
Narrative Update Analysts have nudged their fair value estimate for Altria Group slightly higher to about $48.22, reflecting updated expectations for modest revenue growth, a small adjustment to the discount rate, and a similar forward P/E assumption. This view is underpinned by recent research that points to potentially stabilizing cigarette volumes and a "reasonable" current valuation.Narrative Update • Dec 14
MO: Future Returns Will Depend On Combustible Volume Pressures
Altria Group's updated analyst price target has been trimmed modestly to reflect a slightly lower fair value and higher discount rate, as analysts factor in mixed Q3 results with accelerated Marlboro volume declines and share losses in oral tobacco, partly offset by improving revenue trends and resilient profit margins. Analyst Commentary Bearish analysts have tempered their outlook on Altria following its latest quarterly update, trimming price targets to reflect softer growth expectations and execution risk in the core combustible and oral tobacco franchises.Narrative Update • Oct 25
Dividend Momentum And Regulatory Clarity Will Drive Further Gains Through 2025
Altria Group's analyst price target has been raised by $8 to $72 per share. Analysts cite stronger dividend growth, improved regulatory outlook, and operational momentum as key drivers for this upward revision.Narrative Update • Oct 10
E-Vapor And Oral Tobacco Will Face Regulatory Setbacks
Altria Group's analyst price target has been raised by approximately $1, to $63.83, as analysts cite the company's continued dividend growth, improved profit margin outlook, and prospects for a higher valuation multiple due to favorable regulatory trends. Analyst Commentary Recent analyst reports highlight both the strengths and ongoing risks surrounding Altria Group, following notable price target increases and recognition of the company’s strategic initiatives.Narrative Update • Aug 27
E-Vapor And Oral Tobacco Will Face Regulatory Setbacks
Analysts raised Altria Group’s price target to $62.88, citing its increased dividend, improving regulatory outlook, and sustained earnings through pricing power, while some concerns remain over structural industry headwinds and growth limitations. Analyst Commentary Altria’s recent dividend increase and consistent track record of annual dividend growth support confidence in its capital return program.Analysis Article • Aug 26
Altria Group (NYSE:MO) Is Increasing Its Dividend To $1.06
Altria Group, Inc. ( NYSE:MO ) has announced that it will be increasing its periodic dividend on the 10th of October to...Narrative Update • Aug 07
E-Vapor And Oral Tobacco Will Face Regulatory Setbacks
Despite ongoing structural headwinds, a demanding valuation relative to peers, muted global nicotine growth prospects, and continued analyst preference for British American, the consensus analyst price target for Altria Group has been revised upward from $58.54 to $61.62. Analyst Commentary Structural headwinds impacting Altria's business outlook.Analysis Article • Jul 26
Is Now The Time To Put Altria Group (NYSE:MO) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Apr 30
Altria FQ1: Total Shareholder Yield Exceeds 10%
Summary The updates provided in MO’s FQ1 earnings report reflected some profit pressures and growth headwinds ahead. Sales of smokeable products declined significantly, as MO’s pricing power was not sufficient to completely offset the volume decrease. Oral tobacco products showed slight growth YoY, with the "on!" franchise seeing an 18% shipment volume increase. The attractive capital returns counterbalance the uncertainties well. The total shareholder yield is projected to surpass 10%, driven by generous dividends, consistent share buybacks, and active debt reduction efforts. Read the full article on Seeking AlphaSeeking Alpha • Apr 13
Altria Group: Play Defense If You Expect Uncertain Times
Summary Altria Group is a resilient pick for uncertain times, with strong domestic production facilities and addictive products that ensure steady demand. Despite a 10% fall in traditional cigarette sales in 2024, Altria's non-cyclical, defensive nature and ~50% EBITDA margin provide a safety cushion. Altria's stock has a low Beta, indicating less volatility compared to the S&P 500, making it a stable investment during market downturns. Altria offers attractive valuation, high dividends (over 7% yield), and significant share repurchases, making it a compelling buy amidst market uncertainty. Read the full article on Seeking AlphaSeeking Alpha • Mar 29
Altria: 9%+ Stock Price Appreciation Potential In 2025 On Top Of Dividends
Summary Altria's shareholder returns are attractive, with high and growing dividends and a great share buyback volume. Shareholder returns will be able to continue for the foreseeable future as Altria's underlying operations remain healthy. Altria could see a macroeconomic tailwind as the federal funds rate moves lower potentially allowing the company to see ~9% stock price appreciation in 2025. Read the full article on Seeking AlphaSeeking Alpha • Mar 09
Altria: Trump's Cannabis Pivot May Trigger An Investor Gold Rush
Summary Altria comprises over 20% of my dividend stock portfolio, and I am optimistic about its potential, even without cannabis reform. I believe Trump may enact federal cannabis reform due to political pragmatism and growing public support, especially among younger Republicans. Cannabis reform aligns with states' rights, appealing to conservatives, moderates, and libertarians, and could ensure continued Republican political dominance. Economically, cannabis reform is sensible, with the U.S. industry valued at $30 billion and the potential to create 420,000 jobs and double sales by 2028. Read the full article on Seeking AlphaSeeking Alpha • Feb 07
Altria Q4: A 13% Equity Bond In Disguise
Summary Under the guidance provided in its Q4 earnings report, Altria Group, Inc.'s EBT (earnings before taxes) multiple is only 7.5x, translating a 13.3% EBT yield. This makes it comparable to an equity bond with 13% yield, given the resilience of its business model. But it gets even better as the coupons of bonds do not growth while I expect the earnings of MO to grow at a consistent rate of ~4% per annum. Read the full article on Seeking AlphaSeeking Alpha • Jan 30
Altria: High Yield, Improving Growth
Summary Altria Group reported a double beat in Q4, driven by strong growth from its on! brand, showcasing its robust business model despite a declining smoker base. The tobacco giant's 8% dividend yield and low valuation make it an attractive investment, even with modest earnings growth projections. Altria's focus on price increases and margin growth has led to a 9% EPS increase in Q4, highlighting its ability to convert minor revenue gains into significant profit increases. With a solid dividend and potential for mid-single-digit EPS growth through 2028, Altria offers a reliable return, especially given its low volatility and recession resilience. Read the full article on Seeking AlphaSeeking Alpha • Jan 21
Altria: A Must-Have If You Want Passive Income Right Away
Summary Altria is one of the best companies to build a high passive income right away. But growth is the weak point. Philip Morris is the company to beat at the moment, but NJOY and on! could gain new market share in the coming quarters. Since I expect a slowdown in tech stock valuations, it may be a convenient time to add companies with stable cash flows. Altria is one of them. Read the full article on Seeking AlphaSeeking Alpha • Jan 13
Altria: A High-Yielding Dividend Gem To Buy Now
Summary Since my prior article, Altria's total returns have meaningfully outpaced the S&P 500 index. The company topped analysts' expectations in the third quarter. Altria could be on the cusp of an upgrade in its credit rating to BBB+ from S&P. Shares of the consumer staple could be trading at an 18% discount to fair value. Altria could be positioned for a 57% cumulative total return through 2027. Read the full article on Seeking AlphaSeeking Alpha • Jan 05
Altria Group: HTS Portfolio May Be A Missing Piece In The Puzzle (Rating Upgrade)
Summary Altria's success depends on its HTS market entry via the Horizon JV with Japan Tobacco, leveraging Marlboro's brand strength to capture market share in the space underdeveloped in the US. Other smoke-free initiatives (on!, NJOY) also hold upside potential, but their financial impact hasn't been material yet. I believe HTS portfolio is a missing piece in the puzzle. Altria's current valuation is attractive, and as smoke-free initiatives, especially HTS, gain traction, multiples could be higher. Altria is a 'buy' for patient investors who believe in the market launch of HTS products, but it faces risks from market conditions and competition from established brands like IQOS. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Strategically Building A $100,000 Dividend Portfolio, With Altria As Your Core Holding
Summary Making Altria the largest position of your dividend portfolio could help you to increase its potential for generating dividend income and reducing volatility. This is due to Altria’s Dividend Yield [FWD] of 7.46% and its low 24M Beta Factor of 0.16. In this article, I will demonstrate how you could build a $100,000 dividend portfolio across 2 ETFs and 10 dividend paying companies, while holding Altria as the largest portfolio position. This portfolio offers a reduced risk level, as indicated by a decreased portfolio volatility and a lowered company- and sector-specific concentration risk. The portfolio further integrates dividend income and dividend growth, reflected in its Weighted Average Dividend Yield [TTM] of 4.22% and 5-Year Weighted Average Dividend Growth Rate [CAGR] of 8.91%. Read the full article on Seeking AlphaSeeking Alpha • Dec 12
Altria Is Better Than Philip Morris Per The 10xEBT Rule
Summary This article explains why I like MO better than PM, following the so-called rule of 10xEBT (earnings before taxes). MO features a lower EBT multiple (only about 8.1x of its FWD EBT) than PM (about 15x). Thus, under Buffett’s 10x Pretax Rule, MO offers a much more compelling pretax earnings yield (over 12% vs. PM's 6.4%). In the meantime, I also see higher growth prospects from MO with its higher return on capital employed. Read the full article on Seeking AlphaSeeking Alpha • Dec 02
Altria Group Dividend King Yields Over 7% And Continues To Break Out Toward $60
Summary Altria Group (MO) has surged over 40% in 2024, with potential to exceed $60 by year-end and $70 in 2025. Lower interest rates and Republican control of legislative branches are bullish for MO, reducing operating expenses and potential tax savings. MO's strong Q3 performance and robust market share in tobacco and NJOY products support its undervaluation and dividend growth prospects. MO's consistent dividend increases and potential for further buybacks make it an attractive income-producing asset with a yield exceeding 7%. Read the full article on Seeking AlphaSeeking Alpha • Nov 22
Altria: The Unexpected Tailwind Of An RFK Jr. Nomination
Summary Despite undeniable industry challenges, Altria shares have returned 46% year-to-date. Surprisingly, MO shares have maintained these gains despite potential risks associated with the appointment of RFK Jr. as HHS Secretary. In this article, I weigh the potential risks of RFK Jr.'s MAHA campaign for Altria Group, especially given the tobacco company's concentrated U.S. exposure. However, in addition to the risks, I also highlight why the appointment of RFK Jr. could actually turn out to be a net positive for Altria. Read the full article on Seeking AlphaSeeking Alpha • Nov 03
Altria: Don't Be Fooled By The Market (Rating Downgrade)
Summary Altria Group stock has outperformed the market and its peers, as my bullish thesis played out accordingly. The market will likely focus next on Altria's ability to carve out its market leadership in smokeless products. MO's valuation metrics have narrowed relative to its sector peers and long-term averages. Given the business transition risks, I assess the need for investors to reflect a reasonable discount. As my MO bullish proposition played out to perfection, I explain why MO investors must not throw caution to the wind from here. Read the full article on Seeking AlphaSeeking Alpha • Oct 28
Altria: Dividend Rise Makes Up For Fresh Challenges For NJOY
Summary While Altria's share price hasn't particularly moved in recent months, there have been two crucial developments for it. One, the company's dividend increase has raised the forward yield to 8.2%, which makes it second only to British American Tobacco among the big five tobacco stocks. Two, a patent infringement claim by JUUL against NJOY has gone in JUUL's favor. While Altria continues to fight it out, there's now a question mark on the brand's future. All things considered, however, there's still a Buy case for the stock for income investors with a medium-to-long-term investing horizon. Read the full article on Seeking AlphaShareholder Returns
| MO | US Tobacco | US Market | |
|---|---|---|---|
| 7D | -3.2% | -4.7% | 1.7% |
| 1Y | 16.2% | -7.8% | 25.1% |
Return vs Industry: MO exceeded the US Tobacco industry which returned -7.8% over the past year.
Return vs Market: MO underperformed the US Market which returned 25.1% over the past year.
Price Volatility
| MO volatility | |
|---|---|
| MO Average Weekly Movement | 3.8% |
| Tobacco Industry Average Movement | 9.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1822 | 5,900 | Sal Mancuso | www.altria.com |
Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. It offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and oral tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand.
Altria Group, Inc. Fundamentals Summary
| MO fundamental statistics | |
|---|---|
| Market cap | US$115.14b |
| Earnings (TTM) | US$8.03b |
| Revenue (TTM) | US$20.38b |
14.4x
P/E Ratio5.7x
P/S RatioIs MO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MO income statement (TTM) | |
|---|---|
| Revenue | US$20.38b |
| Cost of Revenue | US$2.57b |
| Gross Profit | US$17.81b |
| Other Expenses | US$9.77b |
| Earnings | US$8.03b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 4.81 |
| Gross Margin | 87.38% |
| Net Profit Margin | 39.42% |
| Debt/Equity Ratio | -778.3% |
How did MO perform over the long term?
See historical performance and comparisonDividends
6.1%
Current Dividend Yield88%
Payout RatioDoes MO pay a reliable dividends?
See MO dividend history and benchmarks| Altria Group dividend dates | |
|---|---|
| Ex Dividend Date | Jun 15 2026 |
| Dividend Pay Date | Jul 10 2026 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 20 days |
Does MO pay a reliable dividends?
See MO dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/18 14:56 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Altria Group, Inc. is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Coleman | Argus Research Company |
| Michael Branca | Barclays |
| Pallav Mittal | Barclays |